PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Cash & equivalents declining -10.40% while Biotechnology shows -7.59% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Near the Biotechnology median of -9.99% for total liquid asset growth. Charlie Munger would check if this is standard for the industry cycle.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth less than half of Biotechnology median of 5.13%. Joel Greenblatt would see a leaner short-term structure vs. peers.
-10.80%
1.25-1.5x the Biotechnology median of -8.38%. Mohnish Pabrai would examine if this advantage is strategic or idle cash buildup.
-9.91%
PP&E growth ≥ 1.5x the Biotechnology median of -3.59%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
-8.44%
≥ 1.5x the Biotechnology median of -2.20%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
≥ 1.5x the Biotechnology median of -6.89%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Below half Biotechnology median of 25.84%. Joel Greenblatt sees fewer expansions than peers.
-12.74%
Above 1.5x Biotechnology median of -6.30%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Below half Biotechnology median of -1.86%. Joel Greenblatt sees more conservative long-term liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
50-75% of Biotechnology median of -4.84%. Mohnish Pabrai notes a relatively conservative approach to liabilities.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
Near Biotechnology median of -4.01%. Charlie Munger sees typical yoy changes in retained earnings.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
≥ 1.5x Biotechnology median of -7.30%. Joel Greenblatt sees stronger equity growth vs. peers.
-10.73%
≥ 1.5x Biotechnology median of -6.91%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Above 1.5x Biotechnology median of -2.94%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
10.43%
Above 1.5x Biotechnology median 3.02%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.